<<In this double blinded randomly controlled pivotal study of zoledronic acid (Novartis), the authors find that at two years time, when the study was discontinued for lack of efficacy, 33% of patients had experienced the primary endpoint of time to distant metastases. P-11 is now going on 2.5 years. It is very reasonable therefore to expect that it will or has reached the median time to distant metastases.>>
Yes, but if Provenge is working well in this population, and with 2/3 of the patients in the trial being in the Provenge arm, wouldn't you expect the trial to take longer than 2.5 years to reach the median time to distant mets?
